Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, Schecter J, Vogel M, Lendvai N, Gries K, Katz E, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho O, Patel N, Florendo E, Karlin L, Weisel K. Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. The Lancet Haematology 2025, 12: e45-e56. PMID: 39756844, DOI: 10.1016/s2352-3026(24)00320-x.Peer-Reviewed Original ResearchConceptsLenalidomide-refractory multiple myelomaStandard of careVisual analogue scaleMultiple myelomaGlobal health statusPatient-reported outcomesCiltacabtagene autoleucelIntention-to-treat populationLenalidomide-refractory diseaseProgression-free survivalECOG performance statusPhase 3 trialEORTC global health statusWorsening of symptomsClinically meaningful improvementsEuropean Organisation for ResearchEQ-5D-5L visual analogue scaleCilta-celEuroQol 5-Dimension 5-LevelOpen-labelImmunomodulatory drugsMedian agePerformance statusSecondary endpointsClinical efficacy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply